VY 9323
Alternative Names: SOD1 gene therapy - Voyager Therapeutics; SOD1 siRNA therapeutic - Voyager Therapeutics; SOD1-ALS; VY-9323; VY-9323-SOD1Latest Information Update: 14 May 2024
At a glance
- Originator Voyager Therapeutics
- Class Small interfering RNA
- Mechanism of Action RNA interference; Superoxide dismutase 1 expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
Most Recent Events
- 08 May 2024 Pharmacodynamics data from a preclinical trial in Amyotrophic lateral sclerosis released by Voyager Therapeutics
- 26 Feb 2024 Voyager Therapeutics expects progressing SOD1 siRNA therapeutic program towards clinical studies
- 06 Dec 2023 Preclinical trials in Amyotrophic lateral sclerosis in USA (IV)